Pepper Bio is a Boston-based drug discovery startup that calls itself the 'world’s first transomics company,' combining DNA, RNA, proteomic and phosphoproteomic data to improve target identification and drug development. The company emphasizes a connected, real-time 'routing context of activity' rather than disconnected multi-omics, likening its approach to Google Maps. Pepper Bio works with pharmaceutical partners and academic labs—including a collaboration with Stanford’s Felsher Lab—to identify and validate therapeutic targets, and its internal pipeline is focused on oncology while also supporting inflammatory and neurodegenerative disease work. CEO Jon Hu and CSO Samantha Dale Strasser highlight that transomics data can improve AI-driven analysis by providing richer inputs. The company is pursuing repurposed assets and is negotiating acquisitions or options to acquire assets for its pipeline. Pepper Bio raised a $6.5 million seed round led by NFX to advance both partnerships and its internal pipeline and to position the company for a subsequent funding round once pilots convert into longer-term partnerships.

Total raised

$7M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2023